Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Melatonin stops melanin production after tyrosinase action, with cyclic GMP mimicking this effect.

This study found that high-dose Cyclosporin A in rats led to significant functional and structural changes, including liver, kidney, and immune system alterations, along with behavioral and hematological effects.

This review discusses the use of cyclosporine in dermatological conditions and its associated monitoring needs and potential side effects, but reports no new research results.

In this study, NAC was observed to counteract the negative effects of cyclophosphamide on hair follicles in mice, preserving both biochemical parameters and hair structure, suggesting its potential as a therapeutic option for chemotherapy-induced hair loss.

This study reports the first documented case of a cat with non-thymoma-associated exfoliative dermatitis showing both clinical and histological resolution after treatment with ciclosporin A, suggesting it may be an effective therapy for this immune-mediated condition.

This study suggests that the CsA-induced inactivation of the CaN/NFAT pathway may suppress TGF-β2 expression in dermal papilla cells, potentially contributing to CsA-associated hypertrichosis.

This study suggests that the COX-2 enzyme plays a role in hair follicle biology, as transgenic overexpression in mice induced hair follicle cycling disturbances and alopecia, which was mitigated by COX-2 inhibition.

Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.

This study developed a rat model for catamenial epilepsy, suggesting that neurosteroid withdrawal may increase seizure frequency and help test new treatments.

Pramipexole can cause side effects like dizziness, sleepiness, hallucinations, and low blood pressure, and it's important to educate patients and keep doses low.

Progesterone treatment improved seizures in a woman with menstrual cycle-related epilepsy, but a wrong medication worsened her condition.

Topical cyclosporine led to significant hair growth in some men with male pattern baldness.

This study found that oral cyclosporine combination therapy led to new hair growth in 71% of patients with severe and refractory alopecia areata, though mild and transient side effects were common.

In this case report, a 75-year-old man with benign essential blepharospasm and Parkinson disease experienced significant symptom relief from dystonia after starting finasteride, suggesting it may be a potential therapeutic option.

This study found that melatonin significantly improved metabolic and reproductive parameters in PCOS-induced rats, with effects similar to metformin.

This study found that cyclosporine A's enhancement of hair growth in mice is partly due to its ability to block the nuclear translocation of apoptosis-inducing factor, slowing the hair follicle transition to the catagen phase.

A specific gene mutation is linked to a hereditary form of dystonia that responds well to certain medications.

This study found that treatment with diphenylcyclopropenone led to more than 75% hair regrowth in 33.3% of patients with alopecia totalis or alopecia universalis, despite notable side effects.

This study found that both ciclosporin A and topical therapy were effective in reducing alopecia and scaling in dogs with idiopathic sebaceous adenitis, with evidence suggesting improved outcomes when both treatments are combined.

This study found that the PPARγ modulator NAC-GED-0507-Levo may protect hair follicles from chemotherapy-induced damage, potentially offering a strategy to address irreversible hair loss in cancer patients.

This study found that clinicians frequently prefer cyclophosphamide over rituximab for induction therapy of childhood-onset systemic lupus erythematosus and ANCA-associated vasculitis, following a high-dose regimen recommended by the NIH.

In this study, photobiomodulation therapy successfully treated hair cycle arrest in a Pembroke Welsh corgi with no adverse effects, suggesting a new potential treatment option for this condition.

This study concluded that monthly pulse IV cyclophosphamide is effective for severe lupus nephritis in Indian patients, achieving complete or partial remission in 68.9% of cases, though longer follow-up is needed.

In this study, 71% of patients with severe and refractory alopecia areata showed new hair growth after treatment with cyclosporine combination therapy, though side effects were common but generally mild.

This study developed a novel mouse model of catamenial epilepsy by manipulating neurosteroid levels and demonstrated that withdrawal increases seizure susceptibility, potentially linked to changes in GABAA receptor-subunit plasticity.

This study found that topical diphenylcyclopropenone was effective in treating severe alopecia areata but had a high relapse rate and was often accompanied by side effects like eczema and lymphadenopathy.

High doses of cyclosporine A increase testosterone conversion, possibly boosting hair growth.

In this study, researchers found that a single oral dose of afoxolaner was safe and effective in treating a severe case of Trixacarus caviae mange in a guinea pig, achieving full remission of clinical signs and mite eradication within 4 weeks without needing repeated treatment.

In this study, researchers identified CENPV as a new CYLD interacting partner that localizes to primary cilia and regulates acetylated tubulin levels, offering insights into the pathogenesis of skin appendage tumors.

This study developed the CATNIP computational model, which uses biological and chemical information to successfully identify drug repurposing opportunities for various conditions, including Parkinson’s disease and Type 2 Diabetes.